Skip to main content
SpringerLink
Log in

The biochemistry of Tourette's Syndrome

  • Review Article
  • Published:
Metabolic Brain Disease Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Alexander G. E., DeLong M. R., and Strick P. L. (1986). Parallel organization of functionally segregated circuits linking basal ganglia and cortex.Ann. Rev. Neurosci. 9:357–381.

    Article  PubMed  Google Scholar 

  • Anderson G. M., Pollak E. S., Chatterjee D., Leckman J. F., Riddle M. A., and Cohen D. J. (1992). Postmortem analysis of subcortical monoamines and amino acids in Tourette syndrome.In Chase T. N., Friedhoff A. J., Cohen D. J. (eds),Advances in Neurology, Vol. 58. Raven Press, New York, pp 123–133.

    Google Scholar 

  • Ang A., Borison R., Dysken M., and Davis J. M. (1982). Reduced excretion of MHPG in Tourette's syndrome.In Friedhoff A. H., Chase T. N. (eds),Advances in Neurology, Vol 35. Raven Press, New York, pp 171–175.

    Google Scholar 

  • Baker G. B., Bornstein R. A., Douglass A. B., Carroll A., and King G. (1991a) Urinary excretion of metabolites of norepinephrine in Tourette's syndrome.Mol. Chem. Neuropathol. 13:225–232.

    Google Scholar 

  • Baker G. B., Bornstein R. A., Rouget A. C., Ashton S. E., van Muyden J. C., and Coutts R. T. (1991b). Phenylethylaminergic mechanisms in attention deficit disorder.Biol. Psychiat. 29:15–22.

    Article  PubMed  Google Scholar 

  • Baker G. B., Bornstein R. A., and Yeragani V. K. (1993). Trace amines and Tourette's syndrome.Neurochem. Res. 18:951–956.

    Article  PubMed  Google Scholar 

  • Black D.W., Noyes R., Goldstein R. B., and Blum N. (1992). A family study of obsessive-compulsive disorder.Arch. Gen. Psychiat. 49:362–368.

    PubMed  Google Scholar 

  • Bornstein R. A. (1991). Tourette's syndrome: two views.J. Clin. Exp. Neuropsychol. 13:381–387.

    Google Scholar 

  • Bornstein R. A., Baker G. B., Carroll A., King G., and Ashton S. (1990). Phenylethylamine metabolism in Tourette's syndrome.J. Neuropsychiat. Clin. Neurosci. 2:408–412.

    Google Scholar 

  • Bornstein R. A. and Baker G. B. (1990). Urinary amines in Tourette's syndrome patients with and without phenylethylamine abnormality.Psychiat. Res. 31:279–286.

    Article  Google Scholar 

  • Bornstein R. A. and Baker G. B. (1991). Neuropsychological performance and urinary phenylethylamine in Tourette's syndrome.J. Neuropsychiat. Clin. Neurosci. 3:417–421.

    Google Scholar 

  • Bornstein R.A. and Baker G.B. (1992a). Urinary indoleamines in Tourette Syndrome patients with obsessive-compulsive characteristics.Psychiat. Res. 41:267–274.

    Article  Google Scholar 

  • Bornstein R. A. and Baker G. B. (1992b). Urinary amines in adults with Tourette's syndrome.Psychiat. Res. 43:277–285.

    Article  Google Scholar 

  • Boulton A. A. (1984). Trace amines and the neurosciences: an overview.In Boulton A. A., Baker G. B., Dewhurst WG, Sandler M (eds),Neurobiology of the Trace Amines. Humana Press, Clifton, NJ, pp 13–24.

    Google Scholar 

  • Breslow M. F., Fankhauser M. P., Potter R. L., Meredith K. E., Misiaszek J., and Hope D. G. (1989). Role of γ-aminobutyric acid in antipanic drug efficacy.Am. J. Psychiat. 146:353–356.

    PubMed  Google Scholar 

  • Brooks D. J., Turjanski N., Sawle G. V., Playford E. D., and Lees A. J. (1992). PET studies on the integrity of the pre and postsynaptic dopaminergic system in Tourette syndrome.In Chase T. N., Friedhoff A. J., Cohen D. J. (eds),Advances in Neurology, Vol. 58. Raven Press, New York, pp 227–232.

    Google Scholar 

  • Bruun R. B. and Budman C. L. (1992). The natural history of Tourette Syndrome.In Chase T. N., Friedhoff A. J., Cohen D. J. (eds),Advances in Neurology, Vol. 58, Raven Press, New York, NY, pp 1–6.

    Google Scholar 

  • Bruun R. D. (1984). Gilles de la Tourette's syndrome: an overview of clinical experience.J. Am. Acad. Child Psychiat. 23:126–133.

    Google Scholar 

  • Bruun R. D. (1988). Subtle and underrecognized side effects of neuroleptic treatment in children with Tourette's disorder.Am. J. Psychiat. 145:621–624.

    PubMed  Google Scholar 

  • Burd L., Kerbeshian J., Wikensheiser M., and Fisher W. (1986). Prevalence of Gilles de la Tourette's syndrome in North Dakota adults.Am. J. Psychiat. 143:787–788.

    PubMed  Google Scholar 

  • Butler I. J., Doslow S. H., Seifert W. E., Caprioli R. M., and Singer H. S. (1979). Biogenic amine metabolism in Tourette syndrome.Ann. Neurol. 6:37–39.

    Article  PubMed  Google Scholar 

  • Caparulo B. K., Cohen D. J., Rothman S. L., Rothman S. L., Young G., Katz J. D.et al. (1981). Computed tomographic brain scanning in children with developmental neuropsychiatric disorders.J. Am. Acad. Child Psychiat. 20:338–357.

    Google Scholar 

  • Chappell P. B. (1994). Commentary on sequential use of opioid antagonists and agonists in Tourette's syndrome.Lancet 343:556.

    Article  Google Scholar 

  • Chappell P. B., Leckman J. F., Riddle M. A., Anderson G. M., Listwack S. J., Ort S. I.et al. (1992). Neuroendocrine and behavioral effects of naloxone in Tourette syndrome.In: Chase T. N., Friedhoff A. J., Cohen D. J. (eds),Advances in Neurology, Vol. 58. Raven Press, New York, pp 253–262.

    Google Scholar 

  • Chappell P. B., Leckman J. F., Scahill L. D., Hardin M. T., Anderson G., and Cohen D. J. (1993). Neuroendocrine and behavioral effects of the selective kappa agonist spiradoline in Tourette's Syndrome: a pilot study.Psychiat. Res. 47:267–280.

    Article  Google Scholar 

  • Chappell P. B., Riddle M., Anderson G., Scahill L., Hardin M., Walker D.et al. (1994). Enhanced stress responsivity of Tourette Syndrome patients underoing lumbar puncture.Biol. Psychiat. 36:35–43.

    Article  PubMed  Google Scholar 

  • Coffey B., Frazier J., and Chen S. (1992). Comorbidity, Tourette syndrome, and anxiety disorders.In: Chase T. N., Friedhoff A. J., Cohen D. J. (eds)Advances in Neurology, Vol. 58. Raven Press, New York, pp 95–104.

    Google Scholar 

  • Cohen B. J., Shaywitz B. A., Caparulo B. K., Young J. G., and Bowers M. B. Jr (1978). Chronic multiple tics of Gilles de la Tourette's disease. CSF acid monoamine metabolites after probenecid administration.Arch. Gen. Psychiat. 35:245–250.

    PubMed  Google Scholar 

  • Cohen D.J., Shaywitz B.A., Young J.C., Carbonari C.M., Nathanson J.A., Lieberman D.et al. (1979). Central biogenic amine metabolism in children with the syndrome of chronic multiple tics of Gilles de la Tourette.J. Am. Acad. Child Psychiat. 18:320–341.

    Google Scholar 

  • Comings D.E. and Comings B.G. (1992). Alternative hypotheses on the inheritance of Tourette syndrome.In Chase T. N., Friedhoff A. J., Cohen D. J. (eds),Advances in Neurology, Vol. 58. Raven Press, New York, pp 189–199.

    Google Scholar 

  • Comings D.E., Himes J.A., and Comings B.G. (1991). An epidemiological study of Tourette's syndrome in a single school district.Neurology 51:463–469.

    Google Scholar 

  • Comings D. E., Muhleman D., Dietz G., Dino M., LeGro R., and Gade R. (1993a). Association between Tourette's syndrome and homozygosity at the dopamine D3 receptor gene.Lancet 341:906.

    Article  PubMed  Google Scholar 

  • Comings D. E., Muhleman D., Dietz G., Dino M., LeGro R., and Gade R. (1993b). Authors' reply.Lancet 341:1483–1484.

    Article  PubMed  Google Scholar 

  • Davis B.A. (1989). Biogenic amines and their metabolites in body fluids of normal, psychiatric, and neurological subjects.J. Chromatogr. 466:89–218.

    Article  PubMed  Google Scholar 

  • Debonnel G. (1993). Current hypotheses on sigma receptors and their physiological role: possible implications in psychiatry.J. Psychiat. Neurosci. 18:157–172.

    Google Scholar 

  • de Groot C.M., Bornstein R.A., and Baker G.B. (1995). Obsessive-compulsive symptom clusters and urinary amine correlates in Tourette Syndrome.J. Nerv. Ment. Dis. (in press).

  • Delgado P.L., Goodman W.K., Price L.H., Heninger G.R., and Charney D.S. (1990). Fluvoxamine/pimozide treatment of concurrent Tourette's and obsessive-compulisve disorder.Br. J. Psychiat. 157:762–765.

    Google Scholar 

  • Demeter S. (1992). Structural imagining in Tourette Syndrome.In Chase T. N., Friedhoff A. J., Cohen D. J. (eds),Advances in Neurology, Vol. 58. Raven Press, New York, pp 201–206.

    Google Scholar 

  • Di Chiara G., Morelli M., and Consolo S. (1994). Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions.Trends in Neurosci. 17:228–233.

    Article  Google Scholar 

  • Dimitsopulos T. and Kuran R. (1993). Tourette's syndrome and nicotine withdrawal.J. Neuropsychiat. 5:108–109.

    Google Scholar 

  • Dingledine R. and McBain C. J. (1994). Excitatory amino acid transmitters.In Siegel G. J., Agranoff B. W., Albers R. W., Molinoff P. B. (eds),Basic Neurochemistry, 5th Ed, Raven Press, New York, NY, pp. 367–387.

    Google Scholar 

  • Dodick D. and Adler C.H. (1992). Tourette's syndrome: current approaches to recognition and management.Postgrad. Med. 92:299–308.

    PubMed  Google Scholar 

  • Done C.J.G. and Sharp T. (1992). Evidence that 5-HT2 receptor activation decreases noradrenaline release in rat hippocampusin vivo.Br. J. Pharmacol. 107:240–245.

    PubMed  Google Scholar 

  • Dourish C. T. (1984). Studies on the mechanisms of action of β-phenylethylamine stereotypy in rodents: implications for a β-phenylethylamine animal model of schizophrenia.In Boulton A. A., Baker G. B., Dewhurst W. G., Sandler M. (eds),Neurobiology of the Trace Amines. Humana Press, Clifton, NJ, pp 389–411.

    Google Scholar 

  • Dursun S. M., Farrar G., Handley S. A., Rickards H., Betts T., and Corbett J. A. (1994). Elevated plasma kynurenine in Tourette syndrome.Mol. Chem. Neuropathol. 21:55–60.

    PubMed  Google Scholar 

  • Dursun S.M. and Handley S.L. (1994). Complex of rapid movements and vocalization induced by RX336-M in mice: possible relevance to Tourette's syndrome.J. Psychopharmacol. 8:27–31.

    Google Scholar 

  • Eiring A., Manier D.H., Bieck P.R., Howells R.D. and Sulser F. (1992). The serontonin/norepinephrine link beyond the β-adrenoceptor.Mol. Brain Res. 16:211–214.

    Article  PubMed  Google Scholar 

  • Elia J. (1993). Drug treatment for hyperactive children. Therapeutic guidelines.Drugs 46:863–871.

    PubMed  Google Scholar 

  • Elridge R., Sweet R., Lake C.R., Ziegler M., and Shapiro A.K. (1977). Gilles de la Tourette's syndrome.Neurology 27:115–127.

    PubMed  Google Scholar 

  • Fang J., Yu P.H., Gorrod J.W., and Boulton A.A. (1995). Inhibition of monoamine oxidase by metabolites of haloperidol: possible cause of depressed monoamine oxidase activity in schizophrenic patients.Psychopharmacol. (in press).

  • Frankel M., Cummings J. L., Robertson M. M., Trimble M. R., Hill M. A., and Benson D. F. (1986). Obsessions and compulsions in Gilles de la Tourette's syndrome.Neurology 36:378–382.

    PubMed  Google Scholar 

  • Freed W. J. (1994). Glutamatergic mechanisms mediating stimulant and antipsychotic drug effects.Neurosci. Biobehav. Rev. 18:111–120.

    Article  PubMed  Google Scholar 

  • Garrick N. A. and Murphy D. L. (1984). Phenylethylamine deamination in the noradrenergic neurotransmitter system.In Boulton A. A., Baker G. B., Dewhurst W. G., Sandler M. (eds),Neurobiology of the Trace Amines. Humana Press, Clifton, NJ, pp. 283–289.

    Google Scholar 

  • Gelernter J., Kennedy J. L., Grandy D. K., Zhou Q. Y., Civelli O., Pauls D. L.et al. (1993). Exclusion of close linkage of Tourette's syndrome to D1-dopamine receptor.Am. J. Psychiat. 150:449–453.

    PubMed  Google Scholar 

  • Gelernter J., Pauls D.L., Leckman J., Kidds K.K., and Kurlan R. (1994). D2 dopamine receptor alleles do not influence severity of Tourette's syndrome — results from four large kindreds.Arch. Neurol. 51:397–400.

    PubMed  Google Scholar 

  • George M.S., Trimble M.R., Costa D. C., Robertson M. M., Ring H. A., and Ell P. J. (1992). Elevated frontal cerebral blood flow in Gilles de la Tourette Syndrome — A Tc-99 (m)-MHPAO SPECT study.Psychiat. Res. Neuroimaging 45:145–151.

    Google Scholar 

  • George M. S., Trimble M. R., and Robertson M. M. (1993). Fluvoxamine and sulpiride in comorbid obsessive-compulsive disorder and Gilles de la Tourette syndrome.Human Psychopharmacol. 8:327–334.

    Article  Google Scholar 

  • Glaze D., Frost J.D. Jr, and Jankovic J. (1983). Sleep in Gilles de la Tourette's syndrome: disorder of arousal.Neurology 33:586–592.

    PubMed  Google Scholar 

  • Goetz C.G. (1992). Clonidine and clonazepam in Tourette Syndrome.In Chase T. N., Friedhoff A. J., Cohen D. J. (eds),Advances in Neurology, Vol. 58,Tourette Syndrome: Genetics, Neurobiology and Treatment. Raven Press, New York, pp 245–251.

    Google Scholar 

  • Golden G.S. (1988). The relationship between stimulant medication and tics.Ped. Ann. 17:405–408.

    Google Scholar 

  • Haber S. N., Kowall N. W., Vonsattel J.P., Bind E.D., and Richardson E.P. Jr (1986). Gilles de la Tourette's syndrome: a postmortem neuropathological and immunohistochemical study.J. Neurol. Sci. 75:225–241.

    Article  PubMed  Google Scholar 

  • Haber S. N. and Wolfer D. (1992). Basal ganglia peptidergic staining in Tourette syndrome: a follow-up study.In Chase T. N., Friedhoff A. J., Cohen D. J. (eds),Advances in Neurology, Vol. 58,Tourette Syndrome: Genetics, Neurobiology and Treatment. Raven Press, New York, pp 145–150.

    Google Scholar 

  • Handley S.L. and Dursun S.M. (1992). Serotonin and Tourette's syndrome: movements such as head-shakes and wet-dog shakes may model human tics.Adv. Biosci. 85:235–253.

    Google Scholar 

  • Hebebrand J., Nöthen M. M., Lehm Kuhl G., Poustka F., Schmidt M., Propping P., and Remschmidt H. (1993). Tourette's syndrome and homozygosity for the dopamine D3 receptor gene.Lancet 341:1483.

    Article  PubMed  Google Scholar 

  • Henderson M.G., Perry K.W., and Fuller R.W. (1993). Possible involvement of dopamine in the long-term serotonin depletion byp-chloroamphetamine and ß,ß-difluoro-p-chloroamphetamine in rats.J. Pharmacol. Exp. Ther. 267:417–424.

    PubMed  Google Scholar 

  • Hewlett W.A. (1993). The use of benzodiazepines in obsessive compulsive disorder and Tourette's syndrome.Psychiat. Ann. 23:309–316.

    Google Scholar 

  • Hudson C. J., Young L. T., Li P. P., and Warsh J. J. (1993). CNS signal transduction in the pathophysiology and pharmacotherapy of affective disorders and schizophrenia.Synapse 13:278–293.

    Article  PubMed  Google Scholar 

  • Jankovic J. (1992). Tourette Syndrome: phenomenology, pathophysiology, genetics, epidemiology and treatment.Curr. Neurol. 13:Chapter 8.

    Google Scholar 

  • Jankovic J. (1993). Deprenyl in attention deficit associated with Tourette's syndrome.Arch. Neurol. 50:286–288.

    PubMed  Google Scholar 

  • Jones R. S. G. (1984). Electrophysiological studies of the possible role of trace amines in synaptic function.In Boulton A. A., Baker G. B., Dewhurst W. G., Sandler M. (eds),Neurobiology of the Trace Amines. Humana Press, Clifton, NJ, pp. 205–223.

    Google Scholar 

  • Juorio A. V. (1982). The effects of some antipsychotic drugs, D-amphetamine and reserpine on the concentration and rate of accumulation of tryptamine and 5-hydroxytryptamine in the mouse striatum.Can. J. Physiol. Pharmacol. 60:376–380.

    PubMed  Google Scholar 

  • Juorio A. V. and Greenshaw A. J. (1986). Tryptamine depletion in the rat striatum following electrolytic lesions of the substantia nigra.Brain Res. 371:386–389.

    Article  Google Scholar 

  • Juorio A. V. and Paterson I. A. (1990). Tryptamine may couple dopaminergic and serotonergic transmission in the brain.Gen. Pharmacol. 5:613–616.

    Google Scholar 

  • Kerbeshian J. and Burd L. (1992). Epidemiology and comorbidity. The North Dakota prevalence studies of Tourette syndrome and other developmental disorders.In: Chase T. N., Friedhoff A. J., Cohen D. J. (eds)Advances in Neurology, Vol. 58. Raven Press, New York, pp 67–74.

    Google Scholar 

  • Klawans H. L., Falk D. K., Nausieda P. A., and Weiner W. J. (1978). Gilles de la Tourette syndrome after long-term chlorpromazine therapy.Neurology 28:1064–1066.

    PubMed  Google Scholar 

  • Knell E. R. and Comings D. E. (1993). Tourette's syndrome and attention deficit hyperactivity disorder: evidence for a genetic relationship.J. Clin. Psychiat. 54:331–337.

    Google Scholar 

  • Koslow S. H. and Cross C. K. (1982). Cerebrospinal fluid monoamine metabolites in Tourette syndrome and their neuroendocrine implications.In Friedhoff A. J., Chase T. N. (eds),Advances in Neurology, Vol. 35. Raven Press, New York, pp. 185–197.

    Google Scholar 

  • Kurlan R., Behr J., Medved L., Shoulson I., Pauls D., and Kidd K. K. (1987). Severity of Tourette's syndrome in one large kindred: implications for determination of disease prevalence rate.Arch. Neurol. 44:268–269.

    PubMed  Google Scholar 

  • Kurlan R., Majumdar L., Deeley C., Mudholkar G. S., Plumb S., Como P. G. (1991). A controlled trial of propoxyphene and naltrexone in patients with Tourette's syndrome.Ann. Neurol. 30:19–23.

    Article  PubMed  Google Scholar 

  • Lake C. R., Ziegler M. G., Elridge R., and Murphy D. L. (1977). Catecholamine metabolism in Gilles de la Tourette's syndrome.Am. J. Psychiat. 134:257–260.

    PubMed  Google Scholar 

  • Langer S. Z. and Arbilla S. (1988). Involvement of newly synthesized catcholamines in the modulation by trace amines of the release of neurotransmitters.In Boulton A. A., Juorio A. V., Downer R. G. H. (eds)Trace Amines: Comparative and Clinical Neurobiology. Humana Press, Clifton, NJ, pp. 191–199.

    Google Scholar 

  • Leckman J. F., Detlor J., Harcherik D. F., Young J. G., Anderson G. M., Shaywitz B. A., and Cohen D. J. (1983). Acute and chronic clonidine treatment in Tourette's syndrome: a preliminary report on clinical response and effect on plasma and urinary catecholamine metabolites, growth hormone and blood pressure.J. Am. Acad. Child Psychiat. 22:433–440.

    Google Scholar 

  • Leckman J. F., Hardin M. T., Riddle M. A., Stevenson J., Ort S. I., and Cohen D. J. (1991). Clonidine treatment of Gilles de la Tourette's Syndrome.Arch. Gen. Psychiat. 48:324–328.

    PubMed  Google Scholar 

  • Leckman J. F., Riddle M. A., Berrettini W. H., Anderson G. M., Hardin M., Chappel P.et al. (1988). Elevated CSF dynorphan A[1-8] in Tourette's syndrome.Life Sci. 43:2015–2023.

    Article  PubMed  Google Scholar 

  • Leckman J. F. and Scahill L. (1990). Possible exacerbation of tics by androgenic steroids (letter).New Engl. J. Med. 322:1674.

    Google Scholar 

  • Leonard H. L., Lenane M. C., Swedo S. E., Rettew D. C., Gershon E. S., and Rapoport J. L. (1992). Tics and Tourette's disorder: a 2- to 7-year follow-up of 54 obsessive-compulsive children.Am. J. Psychiat. 149:1244–1250.

    PubMed  Google Scholar 

  • LeWitt P. A. (1992). Therapeutics of Tourette Syndrome: new medication approaches.In Chase T. N., Friedhoff A. J., Cohen D. J. (eds),Advances in Neurology, Vol 48. Raven Press, New York, pp 263–270.

    Google Scholar 

  • Li S., Sivan S. P., and Hong J. S. (1986). Regulation of the concentration of dynorphin A1-8 in the striatonigral pathway by the dopaminergic system.Brain Res. 398:390–392.

    Article  PubMed  Google Scholar 

  • Lichter D., Majumdar L., and Kurlan R. (1988). Opiate withdrawal unmasks Tourette's syndrome.Clin. Neuropharmacol. 11:559–564.

    PubMed  Google Scholar 

  • Lowe T. L., Cohen D. J., Detlor J., Kremenitzer M. W., and Shaywitz B. A. (1982). Stimulant medications precipitate Tourette's Syndrome.J. Am. Med. Assoc. 247:1729–1731.

    Article  Google Scholar 

  • Manier D. H., Gillesspie D. D., Sanders-Bush E., and Sulser F. (1987). The serotonin/noradrenaline-link in brain. I. The role of noradrenaline and serotonin in the regulation of density and function of β-adrenoceptors and its alteration by desipramine.Naunyn-Schmied Arch. Pharmacol. 335:109–114.

    Google Scholar 

  • Manji H. K. (1992). G proteins: implications for psychiatry.Am. J. Psychiat. 149:746–760.

    PubMed  Google Scholar 

  • Marti-Masso J. F. and Obeso J. A. (1985). Coprolalia associated with hemiballismus: response to tetrabenazine.Clin. Neuropharmacol. 8:189–190.

    PubMed  Google Scholar 

  • Martin L. L., Baker G. B., and Wood P. L. (1988). Tryptamine turnover: effects of drugs.In Boulton A. A., Juorio A. V., Downer R. G. H. (eds),Trace Amines: Comparative and Clinical Neurobiology. Humana Press, Clifton, NJ, pp 95–104.

    Google Scholar 

  • McConville B. J., Norman A. B., Fogelson M. H., and Erenberg G. (1994). Sequential use of opioid antagonists and agonists in Tourette's syndrome.Lancet 343:601.

    Article  PubMed  Google Scholar 

  • McDougle C. J., Goodman W. K., Leckman J. F., Lee N. C., Heninger G. R., and Price L. D. (1994). Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder.Arch. Gen. Psychiat. 51:302–308.

    PubMed  Google Scholar 

  • McGeer P. L. and McGeer E. G. (1989). Amino acid neurotransmitters.In Seigel G. J. (ed),Basic Neurochemistry: Molecular, Cellular and Medical Aspects, 4th Ed. Raven Press, New York, pp 311–332.

    Google Scholar 

  • Mercugliano M. (1993). Psychopharmacology in children with developmental disabilities.Ped. Clin. North Am. 40:593–616.

    Google Scholar 

  • Merikangas J. R., Merikangas K. R., Kopp U., and Hanin I. (1985). Blood choline and response to clonazepam and haloperidol in Tourette's syndrome.Acta Psychiat. Scand. 72:395–399.

    PubMed  Google Scholar 

  • Meuldijk R. and Colon E. J. (1992). Methadone treatment of Tourette's disorder (letter).Am. J. Psychiat. 149:139–140.

    Google Scholar 

  • Moldofsky H., Tullis C., and Lamon R. (1974). Multiple tic syndrome (Gilles de la Tourette's syndrome).J. Nerv. Ment. Dis. 15:282–292.

    Google Scholar 

  • Mousseau D. D. (1993). Tryptamine: a metabolite of tryptophan implicated in various psychiatric disorders.Metab. Brain Dis. 8:1–44.

    Article  PubMed  Google Scholar 

  • Muller N., Putz A., Klages U., Hofschuster E., Straube A., and Ackenheil M. (1994). Blunted growth hormone response to clonidine in Gilles de la Tourette Syndrome.Psychoneuro-endocrinol. 19:335–341.

    Article  Google Scholar 

  • Nestler E. J. and Duman R. S. (1994). G proteins and cyclic nucleotides in the nervous system.In Siegel G. J., Agranoff B. W., Albers R. W., Molinoff P. B. (eds),Basic Neurochemistry, 5th Edition, Raven Press, New York, NY, pp 429–448.

    Google Scholar 

  • Nothen M. M., Hebebrand J., Knapp M., Hebebrand K., Camps A., Von Gontard A.et al. (1994). Association analysis of the dopamine D2 receptor gene in Tourette's syndrome using the haplotype relative risk method.Am. J. Med. Genet. 54:249–252.

    Article  PubMed  Google Scholar 

  • Palfreyman M. G., Schmidt C. J., Sorensen S. M., Dudley M. W., Kehne J. H., Moser P.et al. (1993). Electrophysiological, biochemical and behavioural evidence for 5-HT2 and 5-HT3 mediated control of dopaminergic function.Psychopharmacol. 112:S60-S67.

    Google Scholar 

  • Paterson I. A., Juorio A. V., and Boulton A. A. (1990). 2-Phenylethylamine: a modulator of catecholamine transmission in the mammalian central nervous system?J. Neurochem. 55:1827–1837.

    PubMed  Google Scholar 

  • Pauls D. L., Hurst C. R., Kidd K. K., Kruger S. D., Leckman J. F., and Cohen D. J. (1986a). Tourette syndrome and attention deficit disorder: evidence against a genetic relationship.Arch. Gen. Psychiat. 43:1177–1179.

    PubMed  Google Scholar 

  • Pauls D. L., Leckman J. F., and Cohen D. J. (1993). Familial relationship between Gilles de la Tourette's syndrome, attention deficit disorder, learning disabilities, speech disorders, and stuttering.J. Am. Acad. Child Adolesc. Psychiat. 32:1044–1050.

    Google Scholar 

  • Pauls D. L., Towbin K. E., Leckman J. F., Zahner G. E. P., and Cohen D. J. (1986b). Gilles de la Tourette's syndrome and obsessive compulsive disorder: evidence supporting a genetic relationship.Arch. Gen. Psychiat. 43:1180–1182.

    PubMed  Google Scholar 

  • Peterson B. S., Leckman J. F., Duncan J. S., Wetzles R., Riddle M. A., Hardin M. T., and Cohen D. J. (1994a). Corpus callosum morphology from magnetic resonance images in Tourette's syndrome.Psychiat. Res. Neuroimaging 55:85–99.

    Article  Google Scholar 

  • Peterson B. S., Leckman J. F., Scahill L., Naftolin F., Keefe D., Charest N. J.et al. (1994b). Steroid hormones and Tourette's syndrome — early experience with antiandrogen therapy.J. Clin. Psychopharmacol. 14:131–135.

    PubMed  Google Scholar 

  • Peterson B. S., Riddle M. A., Cohen D. J., Katz L. D., Smith J. C., Hardin M. T., and Leckman J. F. (1993). Reduced basal ganglia volumes in Tourette's syndrome using 3-dimensional reconstruction techniques from magenetic resonance images.Neurology 43:941–949.

    PubMed  Google Scholar 

  • Petty F., Kramer G. L., Fulton M., Moeller F. G., and Rush A. J. (1993). Low plasma GABA is a trait-like marker for bipolar illness.Neuropsychopharmacol. 9:125–132.

    Google Scholar 

  • Price R. A., Kidd K. K., Cohen D. J., Pauls D. L., and Leckman J. F. (1985). A twin study of Tourette's syndrome.Arch. Gen. Psychiat. 42:815–820.

    PubMed  Google Scholar 

  • Quirion R., Gaudrea P., Martel J. C., St. Pierre S., and Zamir N. (1985). Possible interactions between dynorphin and dopaminergic systems in rat basal ganglia and substantia nigra.Brain Res. 331:358–362.

    Article  PubMed  Google Scholar 

  • Rabey J. M., Lewis A., Graff E., and Korczyn A. D. (1992). Decreased3H-quinuclidinyl benzilate binding to lymphocytes in Gilles de la Tourette Syndrome.Biol. Psychiat. 31:889–895.

    Article  PubMed  Google Scholar 

  • Regeur L., Pakkenberg B., Fog R., and Pakkenberg H. (1986). Clinical features and long-term treatment with pimozide in 65 patients with Gilles de la Tourette's syndrome.J. Neurol. Neurosurg. Psychiat. 49:791–795.

    PubMed  Google Scholar 

  • Regeur L., Werdelin L., Pakkenberg H., and Fog R. (1994). Pharmacological treatment of Gilles de la Tourette's syndrome.CNS Drugs 2:191–198.

    Google Scholar 

  • Reveley M. A., Bird R., Stirton R. F., and Dursun S. M. (1994). Microstructureal analysis of the symptoms of Tourette's syndrome and the effects of a trial use of a transdermal nicotine patch.J. Psychopharmacol. Suppl.A30:117.

    Google Scholar 

  • Robertson M. M. (1989). The Gilles de la Tourette Syndrome: the current status.Br. J. Psychiat. 154:147–169.

    Google Scholar 

  • Robertson M. M., Trimble M. R., and Lees A. J. (1988). The psychopathology of Gilles de la Tourette syndrome: a phenomenological analysis.Br. J. Psychiat. 152:383–390.

    Google Scholar 

  • Rogeness G. A., Javars M. A., and Pliszka S. R. (1992). Neurochemistry and child and adolescent psychiatry.J. Am. Acad. Child Adolesc. Psychiat. 31:765–781.

    Google Scholar 

  • Sabatino M., Cannizzaro C., Flugy A., Gagliand M., Mineo A., and Cannizzaro G. (1994). NMDA-GABA interactions in an animal model of behaviour: a gating mechanism from motivation toward psychotic-like symptoms.Eur. Neuropsychopharmacol. 4:103–109.

    Article  PubMed  Google Scholar 

  • Sandor P. (1993). Invited review — Gilles de la Tourette Syndrome: a neuropsychiatric disorder.J. Psychosom. Res. 37:211–226.

    Article  PubMed  Google Scholar 

  • Sandyk R. (1985). The effects of naloxone in Tourette's syndrome.Ann. Neurol. 18:367–368.

    Article  PubMed  Google Scholar 

  • Scahill L., Ort S., and Hardin M. (1993). Tourette's Syndrome, Part I: Definition and Diagnosis and Tourette's Syndrome, Part II: Contemporary approaches to assessment and treatment.Arch. Psychiat. Nurs. 7:203–216.

    Article  Google Scholar 

  • Shannon K. M. (1990). Hemiballismus (review).Clin. Neuropharmacol. 13:413–415.

    PubMed  Google Scholar 

  • Shapiro A. K., Baron M., Shapiro E., and Levitt M. (1984). Enzyme activity in Tourette's syndrome.Arch. Neurol. 41:282–285.

    PubMed  Google Scholar 

  • Shapiro A. K., Shapiro E., and Sweet R. D. (1981). Treatment of tics and Tourette syndrome.In Barbeau A. (ed),Disorders of Movement. JB Lippincott, Philadelphia, pp 105–132.

    Google Scholar 

  • Shapiro A. K., Shapiro E. S., Young J. G., and Feinberg T. (eds) (1988). Gilles de la Tourette Syndrome, 2nd Edition. Raven Press, New York, NY, pp. 229–232.

    Google Scholar 

  • Shea P. A., Wade S. E., Dunlop S. D., and Hendrie H. G. (1984). Effect of chronic haloperidol on the levels of blood and urinary phenylethylamine and phenylacetic acid in rats.In Boulton A. A., Baker G. B., Dewhurst W. G., Sandler M. (eds),Neurobiology of the Trace Amines. Humana Press, Clifton, NJ, pp 271–276.

    Google Scholar 

  • Silver A. A. and Sanberg P. R. (1993). Transdermal nicotine patch and potentiation of haloperidol in Tourette's syndrome.Lancet 342:182.

    Article  Google Scholar 

  • Singer H. S. (1992). Neurochemical analysis of postmortem cortical and striatal brain tissue in patients with Tourette syndrome.In Chase T. N., Friedhoff A. J., Cohen D. J. (eds),Advances in Neurology, Vol 58. Raven Press, New York, pp 135–144.

    Google Scholar 

  • Singer H. S., Hahn I.-H., Krowiak E., Nelson E., and Moran T. (1990). Tourette syndrome: a neurochemical analysis of postmortem cortical brain tissue.Ann. Neurol. 27:443–446.

    Article  PubMed  Google Scholar 

  • Singer H. S., Hahn I.-H., and Moran T. H. (1991). Abnormal dopamine uptake sites in postmortem striatum from patients with Tourette syndrome.Ann. Neurol. 30:558–562.

    Article  PubMed  Google Scholar 

  • Singer H. S., Oshida L., and Coyle J. T. (1984). CSF cholinesterase activity in Gilles de la Tourette's syndrome.Arch. Neurol. 41:756–757.

    PubMed  Google Scholar 

  • Singer H. S., Reiss A. L., Brown J. E., Aylward E. H., Shih B., Chee E.et al. (1993). Volumetric MRI changes in basal ganglia of children with Tourette's syndrome.Neurology 43:950–956.

    PubMed  Google Scholar 

  • Singer H. S. and Rosenberg L. A. (1989). The development of behavioural and emotional problems in Tourette syndrome.Pediatr. Neurol. 5:41–44.

    Article  PubMed  Google Scholar 

  • Singer H. S., Tune L. E., Bulter I. J., Zaczek R., and Coyle J. T. (1982). Clinical symptomatology, CSF neurotransmitter metabolites, and serum haloperidol levels in Tourette Syndrome.In Friedhoff A. J., Chase T. N. eds)Advances in Neurology, Vol. 35, Raven Press, New York, pp. 177–183.

    Google Scholar 

  • Singer H. S. and Walkup J. T. (1991). Tourette syndrome and other tic disorders. Diagnosis, pathophysiology, and treatment.Medicine 70:15–32.

    PubMed  Google Scholar 

  • Singer H. S., Wong D. F., Brown J. E., Brandt J., Krafft L., Shaya E.et al. (1992). Positron emission tomography evaluation of dopamine D2 receptors in adults with Tourette Syndrome.In Chase T. N., Friedhoff A. J., Cohen D. J. eds),Advances in Neurology, Vol 58. Raven Press, New York, pp 233–239.

    Google Scholar 

  • Spiegel R. (1984). Effects of RS-86, an orally active cholinergic agonist, on sleep in man.Psychiatry Res. 11:1–13.

    Article  PubMed  Google Scholar 

  • Stahl S. M. and Berger P. A. (1981). Physostigmine in Tourette syndrome: evidence for cholinergic underactivity.Am. J. Psychiat. 138:240–242.

    PubMed  Google Scholar 

  • Stoetter B., Braun A. R., Randolph C., Gernert J., Carson R. E., Herscovitch P., and Chase T. N. (1992). Functional neuroanatomy of Tourette syndrome. Limbic-motor interactions studies with FDG PET.In Chase T. N., Friedhoff A. J., Cohen D. J. eds),Advances in Neurology, Vol. 48. Raven Press, New York, pp 213–226.

    Google Scholar 

  • Suchowersky O. (1994). Gilles de la Tourette Syndrome.Can. J. Neurol. Sci. 21:48–52.

    PubMed  Google Scholar 

  • Sweeney D., Pickar D., Redmond D. E., and Maas J. (1978). Noradrenergic and dopaminergic mechanisms in Gilles de la Tourette's syndrome.Lancet i:872.

    Article  Google Scholar 

  • Turjanski N., Sawle G. V., Playford E. D., Weeks R., Lammerstma A. A., Lees A. J., and Brooks D. J. (1994). PET studies of the presynaptic and postsynaptic dopaminergic system in Tourette's syndrome. J.Neurol. Neurosurg. Psychiat. 57:688–692.

    PubMed  Google Scholar 

  • Ulas J. and Cotman C. W. (1993). Excitatory amino acid receptors in schizophrenia.Schizophrenia Bull. 19:105–117.

    Google Scholar 

  • van de Wetering B. J. M. and Heutink P. (1993). The genetics of the Gilles de la Tourette syndrome — a review.J. Lab. Clin. Med. 121:638–645.

    PubMed  Google Scholar 

  • Weeks R. A., Lees A. J., and Brooks D. J. (1994). Tourette's syndrome and the opioid system.Lancet 343:1107–1108.

    Article  Google Scholar 

  • Wong D. F., Pearlson G. C., Young L. T., Singer H., Villemagne V., Tune L.et al. (1989). D2 dopamine receptors are elevated in neuropsychiatric disorders other than schizophrenia.J. Cerebral Blood Flow Metab. 9(Suppl. 1):S593.

    Google Scholar 

  • Zametkin A. J., Karoum F., Rapaport J. L., Brown G. L., and Wyatt R. J. (1984) Phenylethylamine excretion in attention deficit disorder.J. Am. Acad. Child Psychiat. 23:310–314.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurochemical Research Unit, Department of Psychiatry, University of Alberta, T6G 2B7, Edmonton, Alberta, Canada

    P. R. Chokka & G. B. Baker

  2. Department of Psychiatry, Ohio State University, Columbus, Ohio, USA

    R. A. Bornstein & C. M. de Groot

Authors
  1. P. R. Chokka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. B. Baker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. A. Bornstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. M. de Groot
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chokka, P.R., Baker, G.B., Bornstein, R.A. et al. The biochemistry of Tourette's Syndrome. Metab Brain Dis 10, 107–124 (1995). https://doi.org/10.1007/BF01991859

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01991859

Search

Navigation